BioCentury
ARTICLE | Company News

TNI BioTech deal

September 3, 2012 7:00 AM UTC

TNI BioTech received exclusive rights to U.S. patents developed by Dr. Bernard Bihari relating to treatments with opioid antagonists such as naltrexone and met-enkephalin to treat cancer, infectious diseases and inflammatory conditions. TNI BioTech plans to use the IP to develop IRT-103, a low-dose naltrexone (LDN). Phase III testing is slated to begin within 12 months. TNI Biotech will initially focus on Crohn's disease, multiple sclerosis (MS) and HIV/AIDS infection. ...